Cellino

Cellino Announces Ed Tekeian as Senior Vice President of Engineering

–Tekeian will oversee the development of Cellino’s scalable manufacturing platform for personalized regenerative medicines. March 18, 2024 09:00 AM Eastern Daylight Time CAMBRIDGE, Mass.–(BUSINESS WIRE)–Cellino Biotech, Inc., a preclinical biotechnology company building an autonomous biomanufacturing platform for personalized regenerative medicine, today announced the expansion of its executive leadership team with the addition of Ed Tekeian as Senior Vice President of Engineering. As an experienced engineering … Continue reading Cellino Announces Ed Tekeian as Senior Vice President of Engineering

ELICIT PLANT

Elicit Plant Announces the Appointment of Slavica Djonovic, Ph.D, as Chief Scientific Officer (CSO)

March 07, 2024 01:28 PM Eastern Standard Time MOULINS-SUR-TARDOIRE, France–(BUSINESS WIRE)–Elicit Plant, a pioneering and rapidly expanding agri-biotech company, announces the appointment of the renowned scientist and a leader in the ag-tech industry, Slavica Djonovic, Ph.D. as Chief Scientific Officer (CSO). An author of more than 20 patent family applications in the space of biomolecular and biological innovations for plant stress, her appointment reflects Elicit … Continue reading Elicit Plant Announces the Appointment of Slavica Djonovic, Ph.D, as Chief Scientific Officer (CSO)

Saghmos Therapeutics

Saghmos Therapeutics Announces Appointment of FDA Veteran Stephen Grant, MD, as Chief Regulatory Officer

Dr. Grant was the former Deputy Director, Division of Cardiology and Nephrology at the FDA GREENWICH, Conn.–(BUSINESS WIRE)–Saghmos Therapeutics, Inc. (Saghmos), a privately held biopharmaceutical company, announced the appointment of Stephen Grant, MD, as Chief Regulatory Officer. Dr. Grant was the former Deputy Director, Division of Cardiology and Nephrology at the FDA. During his more than 20-year career at the FDA, he was responsible for … Continue reading Saghmos Therapeutics Announces Appointment of FDA Veteran Stephen Grant, MD, as Chief Regulatory Officer

Veracyte

Veracyte Completes Acquisition of C2i Genomics

Extends Veracyte’s novel diagnostics platform with whole-genome minimal residual disease capabilities Expands company’s presence across the cancer care continuum SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced it has completed its acquisition of C2i Genomics, Inc., adding whole-genome minimal residual disease (MRD) capabilities to its novel diagnostics platform and expanding the company’s ability to serve patients across the cancer … Continue reading Veracyte Completes Acquisition of C2i Genomics

Bruker

Bruker Announces Agreement to Acquire Chemspeed

Chemspeed Accelerates Bruker’s Laboratory Automation and Digitalization Drive BASEL, Switzerland–(BUSINESS WIRE)–Bruker Corporation (Nasdaq: BRKR) today announced a definitive agreement for the acquisition of Chemspeed Technologies AG, aSwiss provider of vendor-agnostic automated laboratory R&D and QC workflow solutions. Chemspeed is focused on modular automation and robotics solutions for chemical research, pharma drug formulation, materials research for cleantech and consumer applications. “Our team is excited to join Bruker to further … Continue reading Bruker Announces Agreement to Acquire Chemspeed

Variational AI

Variational AI Announces Generative AI Project With Merck

Merck to evaluate Variational AI’s Enki™ generative AI platform to design novel and selective small molecules VANCOUVER, British Columbia–(BUSINESS WIRE)–Variational AI, developer of the Enki™ generative artificial intelligence (AI) platform for drug discovery, today announced a project with Merck Research Labs supported by the CQDM Quantum Leap program. “CQDM is pleased to have facilitated the establishment of collaborations for Variational AI by creating beneficial links … Continue reading Variational AI Announces Generative AI Project With Merck

Osivax

Osivax Appoints Dr. Nicola Groth as Chief Medical Officer

LYON, France–(BUSINESS WIRE)–Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases, announced today the appointment of Dr. Nicola Groth, MD, PhD to its executive committee as Chief Medical Officer. She brings over 25 years of experience in vaccine development with considerable expertise in influenza vaccines, from early-stage clinical development to approval and post-marketing commitments. Dr. Groth joins … Continue reading Osivax Appoints Dr. Nicola Groth as Chief Medical Officer

Aiolos Bio

GSK Enters Agreement to Acquire Aiolos Bio

January 09, 2024 05:52 AM Eastern Standard Time SAN FRANCISCO & LONDON–(BUSINESS WIRE)–GSK plc (LSE/NYSE: GSK) and Aiolos Bio, Inc. (Aiolos) today announced that they have entered into an agreement under which GSK will acquire Aiolos, a clinical-stage biopharmaceutical company focused on addressing the unmet treatment needs of patients with certain respiratory and inflammatory conditions, for a $1 billion upfront payment and up to $400 … Continue reading GSK Enters Agreement to Acquire Aiolos Bio